"Metronidazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed).
Descriptor ID |
D008795
|
MeSH Number(s) |
D02.640.672.500 D03.383.129.308.658.500
|
Concept/Terms |
Metronidazole- Metronidazole
- 2-Methyl-5-nitroimidazole-1-ethanol
- 2 Methyl 5 nitroimidazole 1 ethanol
Metronidazole Hydrochloride- Metronidazole Hydrochloride
- Hydrochloride, Metronidazole
- Metronidazole Monohydrochloride
- Monohydrochloride, Metronidazole
Metronidazole Phosphate- Metronidazole Phosphate
- Phosphate, Metronidazole
- Metronidazole Phosphoester
- Phosphoester, Metronidazole
|
Below are MeSH descriptors whose meaning is more general than "Metronidazole".
Below are MeSH descriptors whose meaning is more specific than "Metronidazole".
This graph shows the total number of publications written about "Metronidazole" by people in this website by year, and whether "Metronidazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2004 | 1 | 0 | 1 |
2005 | 2 | 0 | 2 |
2006 | 3 | 0 | 3 |
2007 | 2 | 0 | 2 |
2008 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
2013 | 0 | 2 | 2 |
2014 | 1 | 2 | 3 |
2015 | 5 | 1 | 6 |
2016 | 0 | 1 | 1 |
2017 | 2 | 1 | 3 |
2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metronidazole" by people in Profiles.
-
Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018 04; 13:507-524.
-
Schwebke JR, Morgan FG, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017 12; 217(6):678.e1-678.e9.
-
Hillier SL, Nyirjesy P, Waldbaum AS, Schwebke JR, Morgan FG, Adetoro NA, Braun CJ. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2017 08; 130(2):379-386.
-
Webster G, Schaller M, Tan J, Jackson JM, Kerrouche N, Sch?fer G. Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis. J Dermatolog Treat. 2017 Aug; 28(5):469-474.
-
Minneci PC, Mahida JB, Lodwick DL, Sulkowski JP, Nacion KM, Cooper JN, Ambeba EJ, Moss RL, Deans KJ. Effectiveness of Patient Choice in Nonoperative vs Surgical Management of Pediatric Uncomplicated Acute Appendicitis. JAMA Surg. 2016 05 01; 151(5):408-15.
-
Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gygax SE, Hilbert DW. Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis. Diagn Microbiol Infect Dis. 2016 Jan; 84(1):1-3.
-
Keating MA, Nyirjesy P. Trichomonas vaginalis Infection in a Tertiary Care Vaginitis Center. Sex Transm Dis. 2015 Sep; 42(9):482-5.
-
Cherian PT, Wu X, Yang L, Scarborough JS, Singh AP, Alam ZA, Lee RE, Hurdle JG. Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. J Antimicrob Chemother. 2015 Nov; 70(11):3061-9.
-
Sobel R, Sobel JD. Metronidazole for the treatment of vaginal infections. Expert Opin Pharmacother. 2015 May; 16(7):1109-15.
-
Chavoustie SE, Jacobs M, Reisman HA, Waldbaum AS, Levy SF, Hillier SL, Nyirjesy P. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis. 2015 Apr; 19(2):129-34.